Overview
Biotechna is an innovative biotechnology company focused on developing targeted therapies using nanotechnology, specifically for oncology. They have created a nanoparticle platform for the delivery of nucleic acids and small molecules, addressing various cancers such as breast, lung, and brain tumors. Additionally, they are advancing RNA and DNA-based products to target undruggable cancer types and enhance treatment effectiveness while reducing toxicity.
Financials
Revenue history (in k)
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
Industry
Bank accounts
Registered as a VAT taxpayer on 2019-07-04. Active
02 1090 1883 0000 0001 5934 4955- 32 1090 1883 0000 0001 4989 7585
- 35 1090 1883 0000 0001 4771 8426
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
MSiG notices
| Publication date | Event | |
|---|---|---|
| Feb 18, 2025 | Commercial Companies Code notice | |
| Nov 30, 2022 | Transformation registered |
Public aid
7 public aid cases recorded, with a total value of $25,512,091.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Dec 28, 2023 | Aid for research and development projects: industrial research | $9.3M$9,319,350 | Prezes Polskiej Agencji Rozwoju Przedsiębiorczości | |
| Dec 28, 2023 | Aid for research and development projects: experimental development | $1.3M$1,266,845 | Prezes Polskiej Agencji Rozwoju Przedsiębiorczości | |
| Sep 27, 2023 | Aid for research and development projects: industrial research | $6.9M$6,873,504 | Prezes Agencji Badań Medycznych |
European Funds
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2024-01-01 | KR2020 - Badania i rozwój pierwszego w swojej klasie leku do stosowania w niedrobnokomórkowym raku płuc | $11.1M$11,146,141 | Fundusze Europejskie dla Nowoczesnej Gospodarki |
Tenders
No recorded participation in tenders.
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
 BDO | BDO register entry | Active |
Authorized Representatives
Manner of representation
In the case of a multi-member management board, each member of the management board is authorised to represent the company independently.
Supervisory board
Beneficial owners
| Person | Rights |
|---|---|
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| GenomedS.A. | $7,373,750.46 | genomed.pl | ||
| MedappS.A. | $3,351,163.61 | medapp.pl | ||
| Scope FluidicsS.A. | $3,082,936.61 | scopefluidics.com | ||
| Centrum Badań i Rozwoju Technologii dla PrzemysłuS.A. | $2,559,521.35 | cbrtp.pl | ||
| IntodnaS.A. | $2,286,118.76 | intodna.com | ||
| Read-GeneS.A. | $2,163,474.84 | read-gene.com | ||
| FamicordtxS.A. | $1,365,068.41 | famicordtx.com | ||
| Saventic Healthsp. z o.o. | $1,089,246.05 | saventic.com | ||
| COS LabP.S.A. | $1,028,123.83 | coslab.pl | ||
| Syventosp. z o.o. | $970,435.47 | syvento.com |
Change history
| Date | Event | |
|---|---|---|
| 2025-02-13 | Share capital change (126,787.00 PLN → 127,883.00 PLN) | |
| 2025-02-13 | Name change (Bs Biotechna → Biotechna) | |
| 2024-11-06 | Share capital change (125,220.00 PLN → 126,787.00 PLN) | |
| 2024-04-08 | Share capital change (122,740.00 PLN → 125,220.00 PLN) | |
| 2023-07-21 | Share capital change (117,900.00 PLN → 122,740.00 PLN) |
FAQ
Last updated: 2026-07-15